Searched for
NICHE ONCOLOGY THERAPY
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- ChrysCapital sets sights on pharma buyout dealsChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 milli...
- Mankind Pharma may offer investors a better entry point after its listingBusiness: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...
- Trend Spotting | Ashish Kacholia betting big on a little-known drug makerBeta Drugs is a pharmaceutical company specialising in branded generics in niche oncology therapy. The company is listed on National Stock ...
- Pankaj Patel owned Cadila ups its India game with AZ’s brandsAs part of the agreement, AZ will sell the following brands of Bricarex, Bricarex-A, Bricanyl, Xylocard, Ceriviprime, Prostodin, Partocin a...
- Quadria Cap concludes Rs 475.31 crore investment in ConcordPrivate equity firm Quadria Capital has concluded a Rs 475.31 crore investment in biopharmaceutical active ingredient manufacturer Concord ...
- Health Ministry to check if Pharma FDI policy mars public healthHealth ministry will hold an inter-ministerial meeting to ensure that the existing FDI in the pharma sector is not at variance with the pub...
- Strides Arcolab gets FDA approval for Oxaliplatin injectionOnco Therapies Ltd, a wholly owned subsidiary of Strides Arcolab today announced that it has received final ANDA approval for Oxaliplatin i...
- Ranbaxy, Zenotech fall on strike by Zenotech employeesFresh trouble spurts for Daiichi Sankyo as Ranbaxy and Zenotech Laboratories- its two Indian subsidiaries-cross swords over the operations ...
- Zenotech employees go on indefinite strike protesting against Ranbaxy's policiesZenotech's employees say that Ranbaxy hasn't cleared several claims pertaining to the sale of drugs and has also failed to pay them for the...
- Dishman to chase high-potency therapiesDishman Pharmaceuticals Ltd, will now focus on the high-potency therapies like steroids, hormones, isotopes and cytotoxics.
- Strides Acrolab: Drug licence, supply gains turn it onTHE Bangalore-based pharma major, Strides Arcolab, saw its stock price rising by 8% on Wednesday on the back of news of the company collabo...
- Speciality players strike deals with local hospitals to expand baseSpeciality hospitals join hands with local healthcare providers to create satellite centres of specialised healthcare.
- Fortis ties up with International OncologyHospital chain Fortis Healthcare has tied up with International Oncology, a US-based company formed by a group of Indian doctors working ov...
- Local pharma eyes layers of US skincare marketThe skincare segment in the US has caught the fancy of Indian drug makers who are looking at the inorganic route to consolidate their prese...
- Zenotech likely to make a pref allotment to RanbaxyZenotech Laboratories will make a preferential allotment of its shares to Ranbaxy Laboratories. In a notice to the BSE, the company said th...
- Ranbaxy to buy 10% in Zenotech for Rs 20 crRanbaxy Laboratories, is close to picking up a 10% stake in Hyderabad-based Zenotech Laboratories for about Rs 20 crore as it moves to plug...
- Zenotech to market Ranbaxy’s oncology products in N AmericaRanbaxy on Wednesday announced a strategic tie-up with Hyderabad-based Zenotech Laboratories for marketing the latter’s oncology products i...
Load More
